ERBB2 and breast cancer: In addition, we have highlighted a potential relationship between the tyrosine kinase receptors TrkA and HER2, demonstrating that the Trk inhibitor GNF-5837 can be used to specifically target TrkA signaling in HER2-positive breast cancer cell lines.